Table 2 Best Response to therapy.

From: Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings

Best Response (n = 31)

n (%)

Progressive disease

5 (16.1)

Complete response

1 (3.2)

Partial response

5 (16.1)

Stable disease

20 (64.5)

  1. Out of 38 patients, 7 patients were considered non-evaluable as scan could not be performed for them.
Back to article page